A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of HPV-negative, PD-L1–positive, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): FORTIFI-HN01.

ficerafusp alfa (BCA101) - Bicara Therapeutics

Keytruda (pembrolizumab) - Merck (MSD)

https://www.asco.org/abstracts-presentations/266965

Renata Ferrarotto; Bhumsuk Keam; Danny Rischin; Melvin Chua; Ralf Reiners; Rita Dalal; Glenn Hanna; John Kaczmar; David Spigel; Christine Chung; Dan Zandberg; Irene Brana; Caroline Even; Kevin Harrington; Lisa Licitra

Apr 21, 2026